{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T22:28:23Z","timestamp":1789597703567,"version":"build-2803163510"},"reference-count":89,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100010699","name":"Monash University Malaysia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010699","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.jval.2023.05.011","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T11:50:58Z","timestamp":1684929058000},"page":"1558-1576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Economic Evaluations of Guideline-Directed Medical Therapies for Heart Failure With Reduced Ejection Fraction: A Systematic Review"],"prefix":"10.1016","volume":"26","author":[{"given":"Wai-Chee","family":"Kuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Jin","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juman","family":"Dujaili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sazzli","family":"Kasim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth Kwing-Chin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siew Li","family":"Teoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jval.2023.05.011_bib1","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijcard.2013.12.028","article-title":"The annual global economic burden of heart failure","volume":"171","author":"Cook","year":"2014","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.jval.2023.05.011_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.15420\/cfr.2016:25:2","article-title":"Global Public health burden of heart failure","volume":"3","author":"Savarese","year":"2017","journal-title":"Card Fail Rev"},{"issue":"36","key":"10.1016\/j.jval.2023.05.011_bib3","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"18","key":"10.1016\/j.jval.2023.05.011_bib4","first-page":"e895","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jval.2023.05.011_bib5","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.15420\/cfr.2021.18","article-title":"The gap to fill: rationale for rapid initiation and optimal titration of comprehensive disease-modifying medical therapy for heart failure with reduced ejection fraction","volume":"7","author":"Brownell","year":"2021","journal-title":"Card Fail Rev"},{"issue":"9","key":"10.1016\/j.jval.2023.05.011_bib6","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2165\/11585990-000000000-00000","article-title":"Decision-analytic models to simulate health outcomes and costs in heart failure: a systematic review","volume":"29","author":"Goehler","year":"2011","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"10.1016\/j.jval.2023.05.011_bib7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s40273-018-0755-x","article-title":"Evaluating cost-effectiveness models for pharmacologic interventions in adults with heart failure: a systematic literature review","volume":"37","author":"Di Tanna","year":"2019","journal-title":"Pharmacoeconomics"},{"issue":"6","key":"10.1016\/j.jval.2023.05.011_bib8","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/nrcardio.2013.60","article-title":"Cost-effectiveness of heart failure therapies","volume":"10","author":"Rohde","year":"2013","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"10.1016\/j.jval.2023.05.011_bib9","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s10741-020-09956-6","article-title":"Cost-effectiveness analyses of sacubitril-valsartan for heart failure","volume":"26","author":"Liu","year":"2021","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.jval.2023.05.011_bib10","doi-asserted-by":"crossref","unstructured":"Febrinasari RP, Putra SE, Hafizhan M, Probandari AN. Cost-effectiveness of sacubitril\u2013valsartan compared to angiotensin-converting enzyme inhibitors in patients with heart failure with reduced ejection fraction [published online April 13, 2022]. J Pharm Pract. https:\/\/doi.org\/10.1177\/08971900221087106.","DOI":"10.1177\/08971900221087106"},{"issue":"3","key":"10.1016\/j.jval.2023.05.011_bib11","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s10198-022-01485-3","article-title":"Model parameters influencing the cost-effectiveness of sacubitril\/valsartan in heart failure: evidence from a systematic literature review","volume":"24","author":"Proudfoot","year":"2023","journal-title":"Eur J Health Econ"},{"issue":"4","key":"10.1016\/j.jval.2023.05.011_bib12","first-page":"168","article-title":"Cost-effectiveness of sacubitril\/valsartan compared with enalapril in patients with heart failure with reduced ejection fraction: a systematic review","volume":"17","author":"Rezapour","year":"2022","journal-title":"J\u00a0Tehran Heart Cent"},{"key":"10.1016\/j.jval.2023.05.011_bib13","doi-asserted-by":"crossref","first-page":"860109","DOI":"10.3389\/fphar.2022.860109","article-title":"Economic evaluation of dapagliflozin in the treatment of patients with heart failure: a systematic review","volume":"13","author":"Wu","year":"2022","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.jval.2023.05.011_bib14","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12962-022-00396-7","article-title":"Cost-effectiveness analysis of dapagliflozin in the management of heart failure with reduced ejection fraction (HFrEF): a systematic review","volume":"20","author":"Mohammadnezhad","year":"2022","journal-title":"Cost Eff Resour Alloc"},{"key":"10.1016\/j.jval.2023.05.011_bib15","doi-asserted-by":"crossref","first-page":"919974","DOI":"10.3389\/fphar.2022.919974","article-title":"Cost effectiveness analyses of pharmacological treatments in heart failure","volume":"13","author":"Lim","year":"2022","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.jval.2023.05.011_bib16","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1586\/14737167.2015.1103185","article-title":"Risk of bias in model-based economic evaluations: the ECOBIAS checklist","volume":"16","author":"Adarkwah","year":"2016","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.jval.2023.05.011_bib17","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"376","author":"Husereau","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.jval.2023.05.011_bib18","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2022"},{"issue":"4","key":"10.1016\/j.jval.2023.05.011_bib19","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jval.2021.01.002","article-title":"Critical appraisal of systematic reviews with costs and cost-effectiveness outcomes: an ISPOR good practices task force report","volume":"24","author":"Mandrik","year":"2022","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.jval.2023.05.011_bib20","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.jval.2012.06.012","article-title":"ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling good research practices\u2014overview: a report of the ISPOR-SMDM Modeling good research practices task force-1","volume":"15","author":"Caro","year":"2012","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2023.05.011_bib21","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1741-7015-11-80","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement","volume":"11","author":"Husereau","year":"2013","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.jval.2023.05.011_bib22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"issue":"6","key":"10.1016\/j.jval.2023.05.011_bib25","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamacardio.2016.1747","article-title":"Cost-effectiveness analysis of sacubitril\/valsartan vs enalapril in patients with heart failure and reduced ejection fraction","volume":"1","author":"Gaziano","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jval.2023.05.011_bib26","author":"Ollendorf"},{"issue":"5","key":"10.1016\/j.jval.2023.05.011_bib27","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jchf.2016.02.007","article-title":"Cost-effectiveness of sacubitril-valsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction","volume":"4","author":"King","year":"2016","journal-title":"JACC Heart Fail"},{"issue":"10","key":"10.1016\/j.jval.2023.05.011_bib28","doi-asserted-by":"crossref","first-page":"681","DOI":"10.7326\/M16-0057","article-title":"Cost-effectiveness of sacubitril-valsartan in patients with heart failure with reduced ejection fraction","volume":"165","author":"Sandhu","year":"2016","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.jval.2023.05.011_bib29","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/phar.2108","article-title":"Cost-effectiveness analysis of sacubitril\/valsartan for the treatment of heart failure with reduced ejection fraction in the United States","volume":"38","author":"Zueger","year":"2018","journal-title":"Pharmacotherapy"},{"issue":"11","key":"10.1016\/j.jval.2023.05.011_bib30","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/jamacardio.2020.2822","article-title":"Cost-effectiveness of sacubitril-valsartan in hospitalized patients who have heart failure with reduced ejection fraction","volume":"5","author":"Gaziano","year":"2020","journal-title":"JAMA Cardiol"},{"issue":"7","key":"10.1016\/j.jval.2023.05.011_bib31","doi-asserted-by":"crossref","first-page":"e2114501","DOI":"10.1001\/jamanetworkopen.2021.14501","article-title":"Cost-effectiveness of dapagliflozin for the treatment of heart failure with reduced ejection fraction","volume":"4","author":"Isaza","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"8","key":"10.1016\/j.jval.2023.05.011_bib32","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1001\/jamacardio.2021.1437","article-title":"Cost-effectiveness of dapagliflozin for treatment of patients with heart failure with reduced ejection fraction","volume":"6","author":"Parizo","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"13","key":"10.1016\/j.jval.2023.05.011_bib33","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.jacc.2012.12.022","article-title":"Incremental cost-effectiveness of guideline-directed medical therapies for heart failure","volume":"61","author":"Banka","year":"2013","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.jval.2023.05.011_bib34","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s40273-018-0709-3","article-title":"Cost-effectiveness analysis of patiromer and spironolactone therapy in heart failure patients with hyperkalemia","volume":"36","author":"Bounthavong","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"10.1016\/j.jval.2023.05.011_bib35","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s40256-020-00425-x","article-title":"Ex ante economic evaluation of Arg389 Genetically targeted treatment with bucindolol versus empirical treatment with carvedilol in NYHA III\/IV heart failure","volume":"21","author":"Alkhatib","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"issue":"12","key":"10.1016\/j.jval.2023.05.011_bib40","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1136\/heartjnl-2016-310661","article-title":"Cost-effectiveness of sacubitril\/valsartan in the treatment of heart failure with reduced ejection fraction","volume":"104","author":"McMurray","year":"2018","journal-title":"Heart"},{"issue":"11","key":"10.1016\/j.jval.2023.05.011_bib41","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/ejhf.1978","article-title":"Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF","volume":"22","author":"McEwan","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.jval.2023.05.011_bib42","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1002\/ehf2.12985","article-title":"Cost-effectiveness of empagliflozin in the UK in an EMPA-REG OUTCOME subgroup with type 2 diabetes and heart failure","volume":"7","author":"Reifsnider","year":"2020","journal-title":"ESC Heart Fail"},{"issue":"3","key":"10.1016\/j.jval.2023.05.011_bib44","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jval.2012.01.004","article-title":"Cost-effectiveness of aldosterone antagonists for the treatment of post-myocardial infarction heart failure","volume":"15","author":"McKenna","year":"2012","journal-title":"Value Health"},{"issue":"21","key":"10.1016\/j.jval.2023.05.011_bib45","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1136\/heartjnl-2014-305673","article-title":"Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms","volume":"100","author":"Lee","year":"2014","journal-title":"Heart"},{"issue":"12","key":"10.1016\/j.jval.2023.05.011_bib46","first-page":"1172","article-title":"Development of a health economic model to evaluate the potential benefits of optimal serum potassium management in patients with heart failure","volume":"21","author":"Bakhai","year":"2018","journal-title":"J\u00a0Med Econ"},{"issue":"9","key":"10.1016\/j.jval.2023.05.011_bib48","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.hlc.2019.03.007","article-title":"Cost-effectiveness of switching patients with heart failure and reduced ejection fraction to sacubitril\/valsartan: the Australian perspective","volume":"29","author":"Chin","year":"2020","journal-title":"Heart Lung Circ"},{"issue":"9","key":"10.1016\/j.jval.2023.05.011_bib49","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1177\/2047487319878953","article-title":"Sacubitril-valsartan versus enalapril for acute decompensated heart failure: a cost-effectiveness analysis","volume":"28","author":"Perera","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jval.2023.05.011_bib50","doi-asserted-by":"crossref","first-page":"750381","DOI":"10.3389\/fcvm.2021.750381","article-title":"Cost-effectiveness evaluation of add-on empagliflozin in patients with heart failure and a reduced ejection fraction from the healthcare system\u2019s perspective in the Asia-Pacific Region","volume":"8","author":"Liao","year":"2021","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"10.1016\/j.jval.2023.05.011_bib51","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s12933-021-01387-3","article-title":"Cost-effectiveness evaluation of add-on dapagliflozin for heart failure with reduced ejection fraction from perspective of healthcare systems in Asia-Pacific region","volume":"20","author":"Liao","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"9","key":"10.1016\/j.jval.2023.05.011_bib52","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1177\/2047487320938272","article-title":"Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective","volume":"28","author":"Savira","year":"2021","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"10.1016\/j.jval.2023.05.011_bib53","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40256-014-0066-3","article-title":"Cost effectiveness of eplerenone in patients with chronic heart failure","volume":"14","author":"Ademi","year":"2014","journal-title":"Am J Cardiovasc Drugs"},{"issue":"18","key":"10.1016\/j.jval.2023.05.011_bib54","doi-asserted-by":"crossref","first-page":"e3531","DOI":"10.1097\/MD.0000000000003531","article-title":"Cost-effectiveness of eplerenone compared to usual care in patients with chronic heart failure and NYHA class II symptoms: an Australian perspective","volume":"95","author":"Ademi","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.jval.2023.05.011_bib55","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cjco.2020.05.009","article-title":"Cost-effectiveness of earlier transition to angiotensin receptor neprilysin inhibitor in patients with heart failure and reduced ejection fraction","volume":"2","author":"Grant","year":"2020","journal-title":"CJC Open"},{"issue":"5","key":"10.1016\/j.jval.2023.05.011_bib57","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40256-016-0177-0","article-title":"Cost effectiveness of eplerenone for the treatment of systolic heart failure with mild symptoms in Alberta, Canada","volume":"16","author":"Thanh","year":"2016","journal-title":"Am J Cardiovasc Drugs"},{"issue":"10","key":"10.1016\/j.jval.2023.05.011_bib58","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s40273-018-0688-4","article-title":"Sacubitril\/valsartan (LCZ696): a novel treatment for heart failure and its estimated cost effectiveness, budget impact, and disease burden reduction in Germany","volume":"36","author":"Gandjour","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"10","key":"10.1016\/j.jval.2023.05.011_bib59","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jval.2019.06.007","article-title":"Cost-effectiveness of sacubitril\/valsartan in Germany: an application of the efficiency frontier","volume":"22","author":"van der Pol","year":"2019","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jval.2023.05.011_bib60","first-page":"174","article-title":"Cost-effectiveness of sacubitril\/valsartan versus enalapril in patients with heart failure and reduced ejection fraction","volume":"21","author":"Liang","year":"2018","journal-title":"J\u00a0Med Econ"},{"issue":"6","key":"10.1016\/j.jval.2023.05.011_bib61","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.clinthera.2019.04.031","article-title":"Cost-utility analysis of sacubitril\/valsartan use compared with standard care in chronic heart failure patients with reduced ejection fraction in South Korea","volume":"41","author":"Park","year":"2019","journal-title":"Clin Ther"},{"issue":"11","key":"10.1016\/j.jval.2023.05.011_bib62","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/ejhf.919","article-title":"Sacubitril\/valsartan in heart failure with reduced ejection fraction: cost and effectiveness in the Italian context","volume":"19","author":"D\u2019Angiolella","year":"2017","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10.1016\/j.jval.2023.05.011_bib63","doi-asserted-by":"crossref","first-page":"597","DOI":"10.2459\/JCM.0000000000000708","article-title":"Sacubitril\/valsartan or an implantable cardioverter-defibrillator in heart failure with reduced ejection fraction patients: A cost-effectiveness analysis","volume":"19","author":"Zac\u00e0","year":"2018","journal-title":"J\u00a0Cardiovasc Med (Hagerstown)"},{"issue":"10","key":"10.1016\/j.jval.2023.05.011_bib64","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.jval.2017.05.013","volume":"20","author":"Ramos","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2023.05.011_bib65","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jval.2016.10.015","article-title":"An economic evaluation of sacubitril\/valsartan for heart failure patients in the Netherlands","volume":"20","author":"van der Pol","year":"2017","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jval.2023.05.011_bib67","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1080\/14737167.2019.1628642","article-title":"Cost-effectiveness of sacubitril\/valsartan for the treatment of patients with heart failure with reduced ejection fraction in Portugal","volume":"20","author":"Borges","year":"2020","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.jval.2023.05.011_bib68","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2147\/CEOR.S107831","article-title":"Cost-effectiveness of eplerenone in NYHA class II chronic heart failure patients with reduced LVEF: an analysis for Greece","volume":"8","author":"Athanasakis","year":"2016","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.jval.2023.05.011_bib69","doi-asserted-by":"crossref","first-page":"w14533","DOI":"10.4414\/smw.2017.14533","article-title":"Cost-effectiveness of sacubitril\/valsartan in chronic heart-failure patients with reduced ejection fraction","volume":"147","author":"Ademi","year":"2017","journal-title":"Swiss Med Wkly"},{"issue":"12","key":"10.1016\/j.jval.2023.05.011_bib70","doi-asserted-by":"crossref","first-page":"101385","DOI":"10.1016\/j.cpcardiol.2022.101385","article-title":"Cost-effectiveness analysis of sacubitril\/valsartan for reducing the use of implantable cardioverter-defibrillator (ICD) and the risk of death in ICD-eligible heart failure patients with reduced ejection fraction","volume":"47","author":"Kaddoura","year":"2022","journal-title":"Curr Probl Cardiol"},{"key":"10.1016\/j.jval.2023.05.011_bib71","doi-asserted-by":"crossref","first-page":"733681","DOI":"10.3389\/fphar.2021.733681","article-title":"Cost-effectiveness of adding SGLT2 inhibitors to standard treatment for heart failure with reduced ejection fraction patients in China","volume":"12","author":"Jiang","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jval.2023.05.011_bib72","author":"Sang"},{"key":"10.1016\/j.jval.2023.05.011_bib73","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.3389\/fphar.2020.01101","article-title":"Sacubitril-valsartan compared with enalapril for the treatment of heart failure: a decision-analytic Markov model simulation in China","volume":"11","author":"Wu","year":"2020","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.jval.2023.05.011_bib74","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1002\/ehf2.12844","article-title":"Cost-effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China","volume":"7","author":"Yao","year":"2020","journal-title":"ESC Heart Fail"},{"issue":"10","key":"10.1016\/j.jval.2023.05.011_bib75","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s40261-021-01079-6","article-title":"Cost-utility analysis of sacubitril-valsartan compared with enalapril treatment in patients with acute decompensated heart failure in Thailand","volume":"41","author":"Krittayaphong","year":"2021","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.jval.2023.05.011_bib76","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijcard.2020.08.017","article-title":"Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction","volume":"322","author":"Krittayaphong","year":"2021","journal-title":"Int J Cardiol"},{"issue":"5","key":"10.1016\/j.jval.2023.05.011_bib77","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s40256-018-0288-x","article-title":"Cost-effectiveness analysis of sacubitril-valsartan compared with enalapril in patients with heart failure with reduced ejection fraction in Thailand","volume":"18","author":"Krittayaphong","year":"2018","journal-title":"Am J Cardiovasc Drugs"},{"issue":"4","key":"10.1016\/j.jval.2023.05.011_bib78","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1080\/14737167.2022.1997595","article-title":"Garc\u00eda \u00c1. Cost-utility of dapagliflozin plus standard treatment compared to standard treatment for the management of heart failure with reduced ejection fraction in Colombia","volume":"22","author":"Gil-Rojas","year":"2022","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"1","key":"10.1016\/j.jval.2023.05.011_bib79","first-page":"450","article-title":"Dapagliflozin cost-effectiveness analysis in heart failure patients in Egypt","volume":"25","author":"Abdelhamid","year":"2022","journal-title":"J\u00a0Med Econ"},{"issue":"4","key":"10.1016\/j.jval.2023.05.011_bib80","doi-asserted-by":"crossref","first-page":"1000145","DOI":"10.4172\/2471-268X\/1000145","article-title":"The cost-effectiveness of EntrestoTM (sacubitril and valsartan) compared with enalapril in managing chronic heart failure in Ghana: decision analytic modelling","volume":"3","author":"Asamani","year":"2017","journal-title":"Health Econ Outcome Res Open Access"},{"issue":"2","key":"10.1016\/j.jval.2023.05.011_bib81","first-page":"81","article-title":"Cost-consequence analysis of sacubitril\/valsartan versus enalapril in chronic heart failure patients with reduced ejection fraction","volume":"43","author":"Gokhale","year":"2021","journal-title":"Appl Med Inform"},{"key":"10.1016\/j.jval.2023.05.011_bib82","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2147\/CEOR.S322740","article-title":"Cost-effectiveness analysis of sacubitril\/valsartan compared to enalapril for heart failure patients in Indonesia","volume":"13","author":"Zakiyah","year":"2021","journal-title":"Clinicoecon Outcomes Res"},{"issue":"6","key":"10.1016\/j.jval.2023.05.011_bib83","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1002\/ehf2.13583","article-title":"Cost-utility analysis of add-on dapagliflozin in heart failure with reduced ejection fraction in the Philippines","volume":"8","author":"Mendoza","year":"2021","journal-title":"ESC Heart Fail"},{"issue":"4","key":"10.1016\/j.jval.2023.05.011_bib84","doi-asserted-by":"crossref","first-page":"e13353","DOI":"10.2196\/13353","article-title":"Impact on readmission reduction among heart failure patients using digital health monitoring: feasibility and adoptability study","volume":"7","author":"Park","year":"2019","journal-title":"JMIR Med Inform"},{"issue":"21","key":"10.1016\/j.jval.2023.05.011_bib85","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.jval.2023.05.011_bib86","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1093\/eurjhf\/hft052","volume":"15","author":"McMurray","year":"2013","journal-title":"Eur J Heart Fail"},{"issue":"15","key":"10.1016\/j.jval.2023.05.011_bib87","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"36","key":"10.1016\/j.jval.2023.05.011_bib88","doi-asserted-by":"crossref","DOI":"10.3310\/hta8360","article-title":"Review of guidelines for good practice in decision-analytic modelling in health technology assessment","volume":"8","author":"Philips","year":"2004","journal-title":"Health Technol Assess"},{"issue":"6","key":"10.1016\/j.jval.2023.05.011_bib89","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jval.2012.06.014","article-title":"State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force\u20133","volume":"15","author":"Siebert","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2023.05.011_bib90","doi-asserted-by":"crossref","first-page":"101008","DOI":"10.1016\/j.eclinm.2021.101008","article-title":"Trends in 30-day readmissions following hospitalisation for heart failure by sex, socioeconomic status and ethnicity","volume":"38","author":"Lawson","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jval.2023.05.011_bib91","doi-asserted-by":"crossref","first-page":"l223","DOI":"10.1136\/bmj.l223","article-title":"Trends in survival after a diagnosis of heart failure in the United Kingdom 2000-2017: population based cohort study","volume":"364","author":"Taylor","year":"2019","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.jval.2023.05.011_bib92","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2165\/00019053-200017050-00005","article-title":"Assessing quality in decision analytic cost-effectiveness models: a suggested framework and example of application","volume":"17","author":"Sculpher","year":"2000","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2023.05.011_bib93","first-page":"64","article-title":"Can we determine the optimal cycle length for which half-cycle correction should always be applied?","volume":"2","author":"Drzal","year":"2014","journal-title":"J\u00a0Health Serv Res Policy"},{"issue":"4","key":"10.1016\/j.jval.2023.05.011_bib94","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/14737167.2019.1557048","article-title":"Valuation of EQ-5D-5L health states: a comparison of seven Asian populations","volume":"19","author":"Wang","year":"2019","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"6","key":"10.1016\/j.jval.2023.05.011_bib95","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jval.2012.04.012","article-title":"Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force\u20137","volume":"15","author":"Eddy","year":"2012","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2023.05.011_bib96","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12933-020-01211-4","article-title":"Cost-effectiveness of GLP-1 receptor agonists versus insulin for the treatment of type 2 diabetes: a real-world study and systematic review","volume":"20","author":"Yang","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"6","key":"10.1016\/j.jval.2023.05.011_bib97","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/j.jval.2021.11.1379","article-title":"Economic evaluation of cognitive behavioral therapy for depression: a systematic review","volume":"25","author":"Li","year":"2022","journal-title":"Value Health"},{"issue":"10","key":"10.1016\/j.jval.2023.05.011_bib98","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1007\/s00262-020-02646-0","article-title":"Economic evaluations of cancer immunotherapy: a systematic review and quality evaluation","volume":"69","author":"Couchoud","year":"2020","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"10.1016\/j.jval.2023.05.011_bib99","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.jval.2022.02.003","article-title":"A\u00a0systematic review of economic evaluations of COVID-19 interventions: considerations of non-health impacts and distributional issues","volume":"25","author":"Podolsky","year":"2022","journal-title":"Value Health"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109830152302613X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109830152302613X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:33:38Z","timestamp":1761096818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109830152302613X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":89,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S109830152302613X"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2023.05.011","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Economic Evaluations of Guideline-Directed Medical Therapies for Heart Failure With Reduced Ejection Fraction: A Systematic Review","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2023.05.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}